Cargando…

Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature

Stanozolol is a 17α-alkylated synthetic anabolic steroid used illegally by bodybuilders. We present a 19-year-old man who was taking 50 mg of stanozolol intramuscularly, every other day for 2 months, to improve muscle mass. On admission, his bilirubin concentration was 44.34 mg/dl. The serum levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Stępień, Piotr M., Reczko, Katarzyna, Wieczorek, Anna, Zarębska-Michaluk, Dorota, Pabjan, Paweł, Król, Teodora, Kryczka, Wiesław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421162/
https://www.ncbi.nlm.nih.gov/pubmed/28856252
http://dx.doi.org/10.5114/ceh.2015.51376
_version_ 1783234546863439872
author Stępień, Piotr M.
Reczko, Katarzyna
Wieczorek, Anna
Zarębska-Michaluk, Dorota
Pabjan, Paweł
Król, Teodora
Kryczka, Wiesław
author_facet Stępień, Piotr M.
Reczko, Katarzyna
Wieczorek, Anna
Zarębska-Michaluk, Dorota
Pabjan, Paweł
Król, Teodora
Kryczka, Wiesław
author_sort Stępień, Piotr M.
collection PubMed
description Stanozolol is a 17α-alkylated synthetic anabolic steroid used illegally by bodybuilders. We present a 19-year-old man who was taking 50 mg of stanozolol intramuscularly, every other day for 2 months, to improve muscle mass. On admission, his bilirubin concentration was 44.34 mg/dl. The serum levels of liver enzymes were normal, with only alanine aminotransferase being slightly elevated. Liver biopsy revealed toxic hepatitis of minor grade with periportal fibrosis and intrahepatic cholestasis. Medical treatment of the patient was conservative. Despite the therapy the patient’s general condition deteriorated – bilirubin level increased to 56.64 mg/dl, and INR rose to 1.7. Then we decided to administer low doses of hydrocortisone. As a result of the treatment, bilirubin concentration was 14.61 mg/dl after 2 weeks. Finally all hepatic enzymes returned to normal values 5 months after stanozolol was discontinued. This treatment appears to be safe and leads to a more rapid reduction of bilirubin.
format Online
Article
Text
id pubmed-5421162
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-54211622017-08-30 Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature Stępień, Piotr M. Reczko, Katarzyna Wieczorek, Anna Zarębska-Michaluk, Dorota Pabjan, Paweł Król, Teodora Kryczka, Wiesław Clin Exp Hepatol Case Report Stanozolol is a 17α-alkylated synthetic anabolic steroid used illegally by bodybuilders. We present a 19-year-old man who was taking 50 mg of stanozolol intramuscularly, every other day for 2 months, to improve muscle mass. On admission, his bilirubin concentration was 44.34 mg/dl. The serum levels of liver enzymes were normal, with only alanine aminotransferase being slightly elevated. Liver biopsy revealed toxic hepatitis of minor grade with periportal fibrosis and intrahepatic cholestasis. Medical treatment of the patient was conservative. Despite the therapy the patient’s general condition deteriorated – bilirubin level increased to 56.64 mg/dl, and INR rose to 1.7. Then we decided to administer low doses of hydrocortisone. As a result of the treatment, bilirubin concentration was 14.61 mg/dl after 2 weeks. Finally all hepatic enzymes returned to normal values 5 months after stanozolol was discontinued. This treatment appears to be safe and leads to a more rapid reduction of bilirubin. Termedia Publishing House 2015-04-30 2015-05 /pmc/articles/PMC5421162/ /pubmed/28856252 http://dx.doi.org/10.5114/ceh.2015.51376 Text en Copyright: © 2015 Clinical and Experimental Hepatology http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Case Report
Stępień, Piotr M.
Reczko, Katarzyna
Wieczorek, Anna
Zarębska-Michaluk, Dorota
Pabjan, Paweł
Król, Teodora
Kryczka, Wiesław
Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature
title Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature
title_full Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature
title_fullStr Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature
title_full_unstemmed Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature
title_short Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature
title_sort severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421162/
https://www.ncbi.nlm.nih.gov/pubmed/28856252
http://dx.doi.org/10.5114/ceh.2015.51376
work_keys_str_mv AT stepienpiotrm severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature
AT reczkokatarzyna severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature
AT wieczorekanna severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature
AT zarebskamichalukdorota severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature
AT pabjanpaweł severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature
AT krolteodora severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature
AT kryczkawiesław severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature